Matthew Sykes
Stock Analyst at Goldman Sachs
(4.04)
# 504
Out of 5,154 analysts
210
Total ratings
54.42%
Success rate
10.22%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $9.61 | -47.97% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.22 | -28.91% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $20.81 | -68.77% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $36.68 | +22.68% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $5.15 | +55.34% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $46.94 | +2.26% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $14.66 | +15.96% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $107.20 | +49.25% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $8.96 | +11.61% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $91.34 | +36.85% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $8.17 | +71.36% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $195.50 | +22.76% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $17.89 | +45.33% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $174.46 | -2.56% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $91.20 | -38.60% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $88.11 | -9.20% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.38 | +8.70% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $198.13 | -4.10% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $2.47 | -29.15% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.55 | +19.72% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $33.85 | +9.31% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $103.50 | -37.20% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $174.49 | +43.27% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.06 | +374.31% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,209.65 | +7.47% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $6.50 | +84.62% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $501.97 | +27.50% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $115.07 | +26.01% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $44.55 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $9.61
Upside: -47.97%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.22
Upside: -28.91%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $20.81
Upside: -68.77%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $36.68
Upside: +22.68%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.15
Upside: +55.34%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $46.94
Upside: +2.26%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $14.66
Upside: +15.96%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $107.20
Upside: +49.25%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $8.96
Upside: +11.61%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $91.34
Upside: +36.85%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $8.17
Upside: +71.36%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $195.50
Upside: +22.76%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $17.89
Upside: +45.33%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $174.46
Upside: -2.56%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $91.20
Upside: -38.60%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $88.11
Upside: -9.20%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.38
Upside: +8.70%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $198.13
Upside: -4.10%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $2.47
Upside: -29.15%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.55
Upside: +19.72%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $33.85
Upside: +9.31%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $103.50
Upside: -37.20%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $174.49
Upside: +43.27%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.06
Upside: +374.31%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,209.65
Upside: +7.47%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $6.50
Upside: +84.62%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $501.97
Upside: +27.50%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $115.07
Upside: +26.01%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $44.55
Upside: -